| pubmed-article:9695716 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9695716 | lifeskim:mentions | umls-concept:C0020155 | lld:lifeskim |
| pubmed-article:9695716 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:9695716 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:9695716 | lifeskim:mentions | umls-concept:C0115201 | lld:lifeskim |
| pubmed-article:9695716 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9695716 | pubmed:dateCreated | 1998-8-20 | lld:pubmed |
| pubmed-article:9695716 | pubmed:abstractText | Dynorphin A(1-13) is a fragment of the endogenous opioid neuropeptide dynorphin A. Previous research suggested that intravenously administered dynorphin A(1-13) has the ability to modulate morphine-induced analgesia. We designed this study to characterize the disposition of intravenous dynorphin immunoreactivity in humans and to determine whether concomitant long-term opioid therapy influenced the pharmacokinetics or side-effects profile of dynorphin A(1-13). | lld:pubmed |
| pubmed-article:9695716 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9695716 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9695716 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9695716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9695716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9695716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9695716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9695716 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9695716 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9695716 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:BroseW GWG | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:HochhausGG | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:GambúsP LPL | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:ShaferS LSL | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:BillardVV | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:SchniderT WTW | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:YoungsE JEJ | lld:pubmed |
| pubmed-article:9695716 | pubmed:author | pubmed-author:MintoC FCF | lld:pubmed |
| pubmed-article:9695716 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9695716 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:9695716 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9695716 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9695716 | pubmed:pagination | 27-38 | lld:pubmed |
| pubmed-article:9695716 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:meshHeading | pubmed-meshheading:9695716-... | lld:pubmed |
| pubmed-article:9695716 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9695716 | pubmed:articleTitle | Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. | lld:pubmed |
| pubmed-article:9695716 | pubmed:affiliation | Departmento de Anestesiologia, Ciutat Sanitaria i Universitaria de Bellvitge, Barcelona, Spain. | lld:pubmed |
| pubmed-article:9695716 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9695716 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9695716 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9695716 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9695716 | lld:pubmed |
